Imovax D.T. Adult (Diphtheria Toxoid, Tetanus Toxoid, Algeldrate)

The toxoids are chemically inactivated forms of the diphtheria and tetanus toxins. After injection, they are processed by antigen‑presenting cells, which display fragments to T cells. This triggers B‑cell activation and the generation of specific antibodies that neutralise the natural toxins, providing protective immunity.

The prescribed dose is determined by the treating healthcare professional. Typically, a single intramuscular or subcutaneous injection is given, with booster doses recommended according to national immunisation guidelines or the patient’s vaccination history.

Safety data for use in pregnancy are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential benefits and risks with their healthcare provider before receiving the vaccine.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Imovax D.T. Adult contains diphtheria and tetanus toxoids combined with the adjuvant algeldrate, which enhances immune response. Its composition and immunogenicity are comparable to other licensed diphtheria‑tetanus vaccines, though formulation differences such as adjuvant type may affect reactogenicity and storage requirements.

The vaccine must be stored refrigerated at 2 °C to 8 °C. It should be kept in the original packaging, protected from light, and must never be frozen or shaken. Proper cold‑chain management is essential to maintain potency until administration.

Imovax D.T. Adult is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, usually into the deltoid muscle. The injection site should be inspected for any adverse reactions after administration, and standard aseptic techniques must be followed.

The most serious adverse events include severe allergic reactions such as anaphylaxis, high fever, seizures, Guillain‑Barré syndrome, and prolonged hypotension. Any signs of a serious reaction require immediate medical evaluation and treatment.

Individuals with a known severe allergy to any component of the vaccine, including diphtheria or tetanus toxoid or the adjuvant algeldrate, should avoid it. Persons with a history of severe anaphylactic reactions to previous doses of diphtheria‑tetanus vaccines should also be excluded, unless a specialist advises otherwise.